Radcliffe Capital Management’s Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 CMRAW Stock Holding History

Radcliffe Capital Management’s Portfolio CMRAW Stock Details CMRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-40,000	Closed	-$1.14K	–	517
2023 Q2	$1.14K	Hold	40,000	–	–	﹤0.01%	571
2023 Q1	$2.01K	Hold	40,000	–	–	﹤0.01%	672
2022 Q4	$49.2K	Hold	40,000	–	–	﹤0.01%	872
2022 Q3	$64K	Hold	40,000	–	–	﹤0.01%	1186
2022 Q2	$106K	Buy	+40,000	New	+$6.55K	﹤0.01%	1224

Other funds holding CMRAW

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Radcliffe Capital Management's CMRAW Position: Q3 2023 in Review

Radcliffe Capital Management sold out of Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 (CMRAW) in Q3 2023, closing a stake of 40,000 shares — an estimated $1.14K sold.

Radcliffe Capital Management first reported a position in CMRAW in Q2 2022 and held it in 5 quarters. The position peaked at $106K in Q2 2022. 15 funds tracked by Wall St. Rank hold CMRAW as of Q3 2023.

Radcliffe Capital Management reported no remaining Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 position as of Q3 2023 after selling out during the quarter.
Radcliffe Capital Management sold 40,000 Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 shares in Q3 2023, an estimated $1.14K.
Radcliffe Capital Management first reported a position in Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 in Q2 2022 and held it in 5 quarters.
Radcliffe Capital Management's Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 position peaked at $106K in Q2 2022.
15 funds tracked by Wall St. Rank held Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.